• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Mercator MedSystems to study its Bullfrog micro-infusion device in below-the-knee critical limb ischemia

November 6, 2017 By Sarah Faulkner

Mercator MedSystemsMercator MedSystems announced last week that it finished enrollment for a six-month trial of its Bullfrog micro-infusion device in patients with below-the-knee critical limb ischemia.

The Emeryville, Calif.-based company’s 120-patient trial was designed to evaluate if Mercator’s Bullfrog device can improve blood flow and reduce the occurrence of restenosis following atherectomy-based revascularization.

Mercator’s micro-infusion device delivers drugs directly through blood vessel walls and into adventital tissues. The Bullfrog device is tipped with a microneedle that is protected by a balloon as it is guided through the vasculature. When the device reaches its intended injection site, the balloon inflates and slides the microneedle through the vessel wall.

“This technology is so hyper-efficient,” CEO Trent Reutiman told Drug Delivery Business News. “It delivers the drug very locally and precisely to the tissue surrounding a blood vessel or an airway.”

The 16-person company has used its device in above-the-knee applications and is now applying Bullfrog for below-the-knee lesions. Reutiman said that the precise delivery that comes along with micro-infusion enables them to use a safer, less toxic drug – like dexamethasone – rather than paclitaxel, which is often used by companies developing drug-coated balloons for the same application.

In Mercator’s latest trial, patients are slated to be randomized either to a treatment group, where they will receive an atherectomy plus dexamethasone via the Bullfrog device, or to a control group, where they will receive an atherectomy-based intervention, the company’s chief executive explained.

After six months, investigators plan to assess if adding dexamethasone to an atherectomy helped keep a patients’ blood vessels open.

“In this category, probably half or more of the patients would be back for repeat intervention within six months, so there’s a really big unmet need to try to solve additional things that can provide more durability and better outcomes for these patients,” Reutiman said. “So we’re excited that if we do we have a benefit in the treatment versus control group, that we would go back to the FDA through the second half of ’18 and hopefully be in position to commercialize the technology for the below the knee market starting in 2019.”

The company is busy with other trials for its Bullfrog device as well, including a below-the-knee application with Pfizer’s temsirolimus drug.

“But there’s no questioning here that there’s a very large clinical development plan that could be executed faster with more cooperation and more resources applied, so I think the only thing that limits us from being bigger and going faster would be more financial resources,” he said. “Hopefully as we generate big data and we put micro-infusion kind of solidly on the map, we’ll attract partnership and resources so that we can continue to work on a broad range of applications and broad range of drugs and biologics.

“It’s not very often you have a true platform delivery technology. It’s peripheral, it’s coronary. We have a version of the product that goes through a bronchoscope for pulmonary. We’re trying to be very focused and deliver value right now, one study at a time.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: Mercator MedSystems

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS